272 related articles for article (PubMed ID: 8270267)
1. Genetically engineered multi-component virus-like particles as veterinary vaccines.
Pearson LD; Roy P
Immunol Cell Biol; 1993 Oct; 71 ( Pt 5)():381-9. PubMed ID: 8270267
[TBL] [Abstract][Full Text] [Related]
2. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection.
Roy P; Bishop DH; LeBlois H; Erasmus BJ
Vaccine; 1994 Jul; 12(9):805-11. PubMed ID: 7975859
[TBL] [Abstract][Full Text] [Related]
3. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.
Stewart M; Dovas CI; Chatzinasiou E; Athmaram TN; Papanastassopoulou M; Papadopoulos O; Roy P
Vaccine; 2012 Mar; 30(12):2131-9. PubMed ID: 22285887
[TBL] [Abstract][Full Text] [Related]
4. DNA vaccine prime and recombinant FPV vaccine boost: an important candidate immunization strategy to control bluetongue virus type 1.
Li J; Yang T; Xu Q; Sun E; Feng Y; Lv S; Zhang Q; Wang H; Wu D
Appl Microbiol Biotechnol; 2015 Oct; 99(20):8643-52. PubMed ID: 26048472
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the immune response afforded by a subunit vaccine candidate against bluetongue virus in mice and sheep.
Mohamed DKA; Du J; Gao S; Tian Z; Zhang G; Huang D; Du R; Kang B; Liu G; Luo J; Yin H
Vet Microbiol; 2018 Jun; 219():40-48. PubMed ID: 29778203
[TBL] [Abstract][Full Text] [Related]
6. Assembly of double-shelled, viruslike particles of bluetongue virus by the simultaneous expression of four structural proteins.
French TJ; Marshall JJ; Roy P
J Virol; 1990 Dec; 64(12):5695-700. PubMed ID: 2173762
[TBL] [Abstract][Full Text] [Related]
7. Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens.
Lobato ZI; Coupar BE; Gray CP; Lunt R; Andrew ME
Vet Immunol Immunopathol; 1997 Nov; 59(3-4):293-309. PubMed ID: 9477479
[TBL] [Abstract][Full Text] [Related]
8. Vesicular stomatitis virus replicon expressing the VP2 outer capsid protein of bluetongue virus serotype 8 induces complete protection of sheep against challenge infection.
Kochinger S; Renevey N; Hofmann MA; Zimmer G
Vet Res; 2014 Jun; 45(1):64. PubMed ID: 24928313
[TBL] [Abstract][Full Text] [Related]
9. From genes to complex structures of bluetongue virus and their efficacy as vaccines.
Roy P
Vet Microbiol; 1992 Nov; 33(1-4):155-68. PubMed ID: 1336237
[TBL] [Abstract][Full Text] [Related]
10. VP2, VP7, and NS1 proteins of bluetongue virus targeted in avian reovirus muNS-Mi microspheres elicit a protective immune response in IFNAR(-/-) mice.
Marín-López A; Otero-Romero I; de la Poza F; Menaya-Vargas R; Calvo-Pinilla E; Benavente J; Martínez-Costas JM; Ortego J
Antiviral Res; 2014 Oct; 110():42-51. PubMed ID: 25057758
[TBL] [Abstract][Full Text] [Related]
11. Replication-Deficient Particles: New Insights into the Next Generation of Bluetongue Virus Vaccines.
Celma CC; Stewart M; Wernike K; Eschbaumer M; Gonzalez-Molleda L; Breard E; Schulz C; Hoffmann B; Haegeman A; De Clercq K; Zientara S; van Rijn PA; Beer M; Roy P
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795442
[TBL] [Abstract][Full Text] [Related]
12. Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge.
Wade-Evans AM; Romero CH; Mellor P; Takamatsu H; Anderson J; Thevasagayam J; Fleming MJ; Mertens PP; Black DN
Virology; 1996 Jun; 220(1):227-31. PubMed ID: 8659119
[TBL] [Abstract][Full Text] [Related]
13. Baculovirus multigene expression vectors and their use for understanding the assembly process of architecturally complex virus particles.
Roy P; Mikhailov M; Bishop DH
Gene; 1997 Apr; 190(1):119-29. PubMed ID: 9185857
[TBL] [Abstract][Full Text] [Related]
14. Plant-produced Bluetongue chimaeric VLP vaccine candidates elicit serotype-specific immunity in sheep.
Mokoena NB; Moetlhoa B; Rutkowska DA; Mamputha S; Dibakwane VS; Tsekoa TL; O'Kennedy MM
Vaccine; 2019 Sep; 37(41):6068-6075. PubMed ID: 31471154
[TBL] [Abstract][Full Text] [Related]
15. Application of bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2.
Feenstra F; Pap JS; van Rijn PA
Vaccine; 2015 Feb; 33(6):812-8. PubMed ID: 25510389
[TBL] [Abstract][Full Text] [Related]
16. Expression of the outer capsid protein VP5 of two bluetongue viruses, and synthesis of chimeric double-shelled virus-like particles using combinations of recombinant baculoviruses.
Loudon PT; Hirasawa T; Oldfield S; Murphy M; Roy P
Virology; 1991 Jun; 182(2):793-801. PubMed ID: 1850928
[TBL] [Abstract][Full Text] [Related]
17. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep.
Boone JD; Balasuriya UB; Karaca K; Audonnet JC; Yao J; He L; Nordgren R; Monaco F; Savini G; Gardner IA; Maclachlan NJ
Vaccine; 2007 Jan; 25(4):672-8. PubMed ID: 17059856
[TBL] [Abstract][Full Text] [Related]
18. Genetically engineered particulate virus-like structures and their use as vaccine delivery systems.
Roy P
Intervirology; 1996; 39(1-2):62-71. PubMed ID: 8957671
[TBL] [Abstract][Full Text] [Related]
19. Development of baculovirus triple and quadruple expression vectors: co-expression of three or four bluetongue virus proteins and the synthesis of bluetongue virus-like particles in insect cells.
Belyaev AS; Roy P
Nucleic Acids Res; 1993 Mar; 21(5):1219-23. PubMed ID: 8385313
[TBL] [Abstract][Full Text] [Related]
20. Bluetongue virus without NS3/NS3a expression is not virulent and protects against virulent bluetongue virus challenge.
Feenstra F; van Gennip RGP; Maris-Veldhuis M; Verheij E; van Rijn PA
J Gen Virol; 2014 Sep; 95(Pt 9):2019-2029. PubMed ID: 24914064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
